stockrow
Friday 6 November 2026
Export BSX’s income statement to Excel — free account
Boston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.6%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
42.73
1.91
−4.28%
Follow BSX
Alert me
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
48.65 | 70.89 | 54.06 | 102.24 | 61.57 | 0.00 | 13.38 | 29.21 | 316.00 | 84.15 |
Piotroski F-Score |
7 | 6 | 7 | 7 | 7 | 4 | 4 | 6 | 6 | 7 |
P/S ratio |
7.03 | 7.85 | 5.90 | 5.19 | 5.08 | 5.14 | 5.86 | 4.97 | 3.83 | 3.54 |
Altman Z-Score |
5.41 | 5.29 | 3.94 | 3.26 | 2.83 | 2.30 | 2.67 | 2.56 | 1.66 | 1.41 |
P/FCF ratio |
38.59 | 49.69 | 46.90 | 69.28 | 45.43 | 44.52 | 45.53 | 6,100.57 | 31.29 | 35.57 |
Altman Z″-Score (non-manufacturers) |
2.81 | 2.08 | 2.13 | 1.90 | 1.64 | 1.41 | 0.93 | (0.24) | (1.00) | (0.88) |
Beneish M-Score |
(2.49) | (2.53) | (2.48) | (2.46) | (2.44) | (2.87) | (1.87) | (2.12) | (2.77) | (2.59) |
P/Operating CF |
103.49 | 90.27 | 87.82 | 81.56 | 126.40 | 75.68 | 90.93 | 2,568.66 | 50.64 | 43.94 |
P/B ratio |
5.77 | 5.97 | 4.30 | 3.75 | 3.63 | 3.32 | 4.53 | 5.59 | 4.94 | 4.41 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
7.50 | 8.47 | 6.48 | 5.82 | 5.68 | 5.89 | 6.77 | 5.67 | 4.43 | 4.17 |
EV/EBITDA |
29.97 | 33.28 | 25.65 | 25.33 | 25.39 | 36.99 | 47.93 | 37.00 | 31.18 | 78.28 |
EV/Operating CF |
33.22 | 41.27 | 36.87 | 48.38 | 36.13 | 38.69 | 39.60 | 179.72 | 28.10 | 29.60 |
EV/FCF |
41.18 | 53.60 | 51.49 | 77.71 | 50.80 | 51.00 | 52.62 | 6,964.32 | 36.19 | 41.91 |
Quick Ratio |
0.90 | 0.46 | 0.63 | 0.76 | 0.87 | 0.89 | 0.42 | 0.33 | 0.31 | 0.47 |
Current Ratio |
1.62 | 1.08 | 1.32 | 1.51 | 1.48 | 1.82 | 0.97 | 0.76 | 0.68 | 0.90 |
Net Debt/EBITDA |
1.88 | 2.43 | 2.29 | 2.75 | 2.68 | 4.70 | 3.72 | 2.84 | 2.54 | 4.15 |
Debt/Assets |
26.19% | 27.28% | 25.91% | 27.52% | 28.13% | 29.71% | 32.74% | 33.60% | 29.49% | 30.31% |
Debt/Equity |
0.47 | 0.49 | 0.47 | 0.51 | 0.55 | 0.60 | 0.72 | 0.81 | 0.80 | 0.81 |
Asset Turnover |
0.48 | 0.45 | 0.42 | 0.39 | 0.38 | 0.32 | 0.42 | 0.49 | 0.49 | 0.46 |
Operating CF/Net income |
1.56 | 1.85 | 1.59 | 2.38 | 1.90 | (13.11) | 0.39 | 0.19 | 13.71 | 3.41 |
Capex/Depreciation |
(0.62) | (0.48) | (0.57) | (0.45) | (0.37) | (0.22) | (0.41) | (0.33) | (0.38) | (0.42) |
Interest Coverage |
10.35 | 8.54 | 8.84 | 3.50 | 3.51 | (0.22) | 3.21 | 6.25 | 5.61 | 1.92 |
| 12.47% | 8.92% | 8.46% | 3.75% | 6.17% | (0.79%) | 41.59% | 21.24% | 1.51% | 5.32% | |
| 6.98% | 4.97% | 4.64% | 1.98% | 3.13% | (0.37%) | 18.23% | 8.35% | 0.56% | 1.92% | |
ROIC |
6.65% | 5.04% | 5.27% | 4.02% | 3.15% | (0.22%) | 4.01% | 6.02% | 6.46% | 2.32% |
Return on Tangible Assets |
39.21% | 48.57% | 35.36% | 14.58% | 22.93% | (2.26%) | 245.82% | 318.29% | (77.04%) | 27.07% |
Average Days of Receivables |
53.20 | 55.75 | 57.11 | 56.70 | 54.59 | 56.37 | 62.15 | 59.75 | 62.45 | 64.07 |
Research and Development Expense of Revenue |
10.22% | 9.64% | 9.93% | 10.43% | 10.13% | 11.53% | 10.94% | 11.33% | 11.02% | 10.97% |
Selling, General and Administrative Expense of Revenue |
34.54% | 35.93% | 36.77% | 36.01% | 37.08% | 38.66% | 37.32% | 37.05% | 37.16% | 37.90% |
Intangible Assets out of Total Assets |
0.58 | 0.60 | 0.58 | 0.58 | 0.56 | 0.52 | 0.59 | 0.68 | 0.67 | 0.69 |
Share Based Compensation of Revenue |
1.49% | 1.59% | 1.64% | 1.73% | 1.63% | 1.71% | 1.46% | 1.43% | 1.40% | 1.38% |
Graham Net Nets |
(0.07) | (0.08) | (0.11) | (0.14) | (0.15) | (0.17) | (0.19) | (0.17) | (0.24) | (0.27) |
Graham Number |
27.00 | 20.59 | 17.99 | 11.15 | 13.47 | 0.00 | 27.54 | 13.12 | 3.03 | 5.39 |
Earnings Yield |
2.06% | 1.41% | 1.85% | 0.98% | 1.62% | (0.34%) | 7.47% | 3.42% | 0.32% | 1.19% |
Free Cash Flow Yield |
2.59% | 2.01% | 2.13% | 1.44% | 2.20% | 2.25% | 2.20% | 0.02% | 3.20% | 2.81% |
Revenue per Share |
13.56 | 11.38 | 9.80 | 8.87 | 8.36 | 7.00 | 7.71 | 7.11 | 6.60 | 6.18 |
Operating CF per Share |
3.06 | 2.33 | 1.72 | 1.07 | 1.31 | 1.06 | 1.32 | 0.22 | 1.04 | 0.87 |
Capex per Share |
(0.59) | (0.54) | (0.49) | (0.40) | (0.38) | (0.26) | (0.33) | (0.22) | (0.23) | (0.26) |
Free Cash Flow per Share |
2.47 | 1.80 | 1.23 | 0.66 | 0.94 | 0.81 | 0.99 | 0.01 | 0.81 | 0.62 |
Cash per Share |
1.33 | 0.28 | 0.60 | 0.65 | 1.35 | 1.22 | 0.16 | 0.11 | 0.14 | 0.14 |
Shareholders Equity per Share |
16.53 | 14.95 | 13.44 | 12.28 | 11.69 | 10.82 | 9.97 | 6.32 | 5.12 | 4.96 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
16.53 | 14.95 | 13.44 | 12.28 | 11.69 | 10.82 | 9.97 | 6.32 | 5.12 | 4.96 |
Free Cash Flow |
3,658.00 | 2,645.00 | 1,792.00 | 950.00 | 1,330.00 | 1,144.00 | 1,382.00 | 8.00 | 1,107.00 | 835.00 |
Working Capital |
3,355.00 | 521.00 | 1,581.00 | 1,957.00 | 2,043.00 | 3,013.00 | (167.00) | (1,257.00) | (1,832.00) | (348.00) |
Capital Expenditures |
(876.00) | (790.00) | (711.00) | (576.00) | (540.00) | (364.00) | (454.00) | (302.00) | (319.00) | (347.00) |
Net Current Asset Value |
(10,407.00) | (10,472.00) | (9,092.00) | (9,136.00) | (9,290.00) | (8,757.00) | (11,989.00) | (8,270.00) | (8,208.00) | (8,124.00) |
EV/EBIT |
41.70 | 54.42 | 39.38 | 44.82 | 56.39 | 0.00 | 47.93 | 37.00 | 31.18 | 78.28 |
Capex to Sales |
0.04 | 0.05 | 0.05 | 0.05 | 0.05 | 0.04 | 0.04 | 0.03 | 0.04 | 0.04 |
Price to Operating Income |
39.08 | 50.45 | 35.87 | 39.96 | 50.43 | 0.00 | 41.48 | 32.41 | 26.95 | 66.45 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.35 | 0.50 | 0.44 | 0.52 | 0.65 | 0.79 | 0.54 | 0.52 | 0.50 | 0.51 |
Cash ROIC |
9.66% | 7.98% | 6.08% | 3.46% | 4.82% | 4.37% | 5.73% | 0.05% | 8.64% | 6.73% |
Accounts Receivable Turnover |
7.32 | 7.00 | 6.78 | 6.77 | 7.19 | 5.90 | 6.25 | 6.23 | 5.99 | 6.11 |
Accounts Payable Turnover |
5.91 | 5.53 | 4.82 | 4.78 | 5.68 | 6.57 | 6.99 | 6.40 | 5.31 | 7.39 |
Inventory Turnover |
2.16 | 1.99 | 2.00 | 2.28 | 2.51 | 2.37 | 2.27 | 2.51 | 2.55 | 2.46 |
Average Days of Payables |
67.12 | 66.65 | 79.13 | 79.53 | 78.09 | 54.04 | 63.49 | 45.28 | 74.60 | 67.31 |
Days of Inventory on Hand |
172.67 | 195.10 | 208.67 | 172.26 | 158.35 | 142.31 | 184.96 | 151.29 | 151.74 | 143.80 |
Average Receivables |
2,742.00 | 2,393.00 | 2,099.00 | 1,874.00 | 1,654.50 | 1,679.50 | 1,718.00 | 1,578.00 | 1,510.00 | 1,373.50 |
Average Payables |
1,052.00 | 951.00 | 902.00 | 828.00 | 653.50 | 527.50 | 445.50 | 439.50 | 488.50 | 328.00 |
Average Inventory |
2,876.50 | 2,647.00 | 2,175.50 | 1,738.50 | 1,480.50 | 1,465.00 | 1,372.50 | 1,122.00 | 1,016.50 | 985.50 |
Average Assets |
41,534.00 | 37,265.50 | 33,802.50 | 32,349.00 | 31,503.00 | 30,671.00 | 25,782.00 | 20,020.50 | 18,569.00 | 18,114.50 |
Average Common Equity |
23,237.00 | 20,766.00 | 18,551.50 | 17,098.50 | 15,975.00 | 14,602.00 | 11,301.00 | 7,868.00 | 6,872.00 | 6,526.50 |
Columns are period end dates · fundamentals updated 5 Nov 2026